Preventing cardiovascular dis- ease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113:2943 6. 27. Rasoul S, Ottervanger JP, de Boer M-J, et al. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST- elevation myocardial infarction. Coron Artery Dis. 2009;20:415 21. 28. De Luca G, Gibson CM, Bellandi F, et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mor- tality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atheroscle- rosis. 2009;207:181 5. 29. Svensson A-M, McGuire DK, Abrahamsson P, et al. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26:1255 61. 30. Worthley MI, Shrive FM, Anderson TJ, et al. Prognostic implication of hyperglycemia in myocardial infarction and primary angioplasty. Am J Med. 2007;120:643 7.e1 7. 31. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and in- creased risk of death after myocardial infarction in patients with and with- out diabetes: a systematic overview. Lancet. 2000;355:773 8. 32. Timmer JR, van der Horst ICC, Ottervanger JP, et al. Prognostic value of admission glucose in non-diabetic patients with myocardial infarction. Am Heart J. 2004;148:399 404. 33. Ishihara M, Kagawa E, Inoue I, et al. Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol. 2007;99:1674 9. 34. Porter A, Assali AR, Zahalka A, et al. Impaired fasting glucose and out- comes of ST-elevation acute coronary syndrome treated with primary per- cutaneous intervention among patients without previously known diabetes mellitus. Am Heart J. 2008;155:284 9. 35. Marso SP, Miller T, Rutherford BD, et al. 